Jpmorgan Chase & CO Xeris Biopharma Holdings, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,043,441 shares of XERS stock, worth $3.74 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,043,441
Previous 391,960
166.21%
Holding current value
$3.74 Million
Previous $1.12 Million
216.65%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding XERS
# of Institutions
152Shares Held
60MCall Options Held
148KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$37 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$28.3 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$18.3 Million62.59% of portfolio
-
Geode Capital Management, LLC Boston, MA3.35MShares$12 Million0.0% of portfolio
-
State Street Corp Boston, MA3.2MShares$11.5 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $487M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...